Project Details
Description
PROJECT SUMMARY
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that causes memory loss and cognitive
decline. Synaptic dysfunction and loss correlates strongly with cognitive impairment in AD. Aging is the leading
risk factor for AD, and epigenetic mechanisms involving histone deacetylases (HDACs) play an important role in
aging and age-related neurodegenerative disorders. Among the 11 zinc-dependent HDACs, HDAC9 is the most
abundant isoform in the brain, found exclusively in neurons. We provide key preliminary data showing that
HDAC9 expression in the hippocampus and prefrontal cortex (PFC) diminishes with aging in wild-type mice, and
that reduced HDAC9 expression precedes the onset of amyloid deposition in the APP/PS1 mouse model of AD.
Consistent with these preclinical findings, AD patients exhibited decreased HDAC9 expression in the dorsolateral
PFC. Moreover, global or hippocampal CA1-specific deletion of HDAC9 induces cognitive impairment and
impairs synaptic plasticity, while HDAC9 overexpression produces cognitive-enhancing effects. We hypothesize
that reduced neuronal HDAC9 mediates cognitive decline, synaptic dysfunction and other
neuropathologies associated with brain aging and AD. To test this hypothesis, we propose three specific
aims. In Aim 1, we will test the hypothesis that loss of HDAC9 in hippocampal and PFC neurons mediates age-
and AD-related neuropathology and cognitive impairment. In Aim 2, we will test the hypothesis that the histone
methyltransferase EZH2 [the catalytic component of the polycomb repressive complex 2 (PRC2), which
catalyzes repressive H3K27me3 modifications at gene promoters] epigenetically silences HDAC9 expression in
the hippocampus and PFC during aging and in AD. In Aim 3, we will test the hypothesis that neuronal pentraxin
2 (NP2), nerve growth factor inducible (VGF), and brain-derived neurotrophic factor (BDNF) mediate the
downstream effects of HDAC9 on hippocampal synaptic plasticity and cognition. We expect that the results will
provide insight into molecular mechanisms underlying the epigenetic control of genes related to aging and AD
and offer potential targets for future therapeutic interventions.
Status | Active |
---|---|
Effective start/end date | 2/1/22 → 1/31/25 |
Funding
- National Institute on Aging: $567,615.00
- National Institute on Aging: $510,853.00
- National Institute on Aging: $567,615.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.